Fig. 6.

Combination strategy of G1T48 and the CDK4/6 inhibitor lerociclib in vivo in an estrogen-deprived xenograft model. Ovariectomized vehicle-treated female nu/nu mice bearing LTED xenograft were randomized to treatment with vehicle, lerociclib (50 or 100 mg/kg) or palbociclib (100 mg/kg) (a) or G1T48 (5 or 100 mg/kg) or fulvestrant (25 mg/kg) (b), alone or together (c), p.o. daily for 28 days. 2-way ANOVA comparison of average tumor volumes throughout treatment, followed by Bonferroni multiple comparison test, indicated significant tumor growth inhibition by all treatments, as well as increased response to the combination of G1T48 (30 mg/kg) and lerociclib. Error bars represent SEM